Barclays (LON:BARC) analyst Luke Sergott maintained a Hold rating on Icon (NASDAQ:ICLR) plc on Thursday, setting a price target of $210, which is approximately 2.34% above the present share price of $205.2.
Sergott expects Icon plc to post earnings per share (EPS) of $1.92 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Icon, with an average price target of $227.44.
The analysts price targets range from a high of $280 to a low of $200.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $760.23 million and a net profit of $119.86 million. The company's market cap is $10.83 billion.
According to TipRanks.com, Barclays analyst Luke Sergott is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 65.1% and a 86.67% success rate.
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.